Search hospitals > Washington > Bellevue

Overlake Medical Center

Claim this profile
Bellevue, Washington 98004
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Breast cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
175 reported clinical trials
5 medical researchers
Photo of Overlake Medical Center in BellevuePhoto of Overlake Medical Center in BellevuePhoto of Overlake Medical Center in Bellevue

Summary

Overlake Medical Center is a medical facility located in Bellevue, Washington. This center is recognized for care of Lung Cancer, Breast Cancer, Breast cancer, Cancer, Pancreatic Cancer and other specialties. Overlake Medical Center is involved with conducting 175 clinical trials across 319 conditions. There are 5 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, Kathleen Gibson, MD, and John A. Keech.

Area of expertise

1Lung Cancer
Global Leader
Overlake Medical Center has run 29 trials for Lung Cancer. Some of their research focus areas include:
Stage IV
Stage II
Stage III
2Breast Cancer
Global Leader
Overlake Medical Center has run 27 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive

Top PIs

Clinical Trials running at Overlake Medical Center

Bladder Cancer
Lung Cancer
Bladder Carcinoma
Kidney Cancer
Esophageal cancer
Testicular cancer
Pancreatic Cancer
Pancreatic Carcinoma
Gastric cancer
Cancer
Image of trial facility.

Eribulin + Chemotherapy

for Bladder Cancer

This phase III trial compares the usual chemotherapy treatment to eribulin plus gemcitabine in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as eribulin, gemcitabine, docetaxel, paclitaxel, and sacituzumab govitecan work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial aims to see whether adding eribulin to standard of care chemotherapy may work better in treating patients with metastatic urothelial cancer.
Recruiting2 awards Phase 3
Image of trial facility.

Immunotherapy + Targeted Therapy

for Genitourinary Cancers

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no treatment options compared to giving cabozantinib, nivolumab, or ipilimumab alone.
Recruiting1 award Phase 221 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Overlake Medical Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security